REG - Novacyt S.A. - Director/PDMR Shareholding

Novacyt SAAnnouncement

Today 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260330:nRSd6764Ya&default-theme=true

RNS Number : 6764Y  Novacyt S.A.  30 March 2026

 

Novacyt S.A.

("Novacyt" or the "Company")

 

Director/PDMR Shareholding

 

Paris, France, and Manchester, UK - 30 March 2026 - Novacyt S.A. (EURONEXT
GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company
with a broad portfolio of integrated technologies and services, announces that
it has been notified that, on 26 and 27 March 2026, the following Directors
purchased ordinary shares of €1/15 each in the Company (the "Ordinary
Shares"):

 

 Director    Title     Number of Ordinary Shares purchased  Average price paid per Ordinary Share  Resultant beneficial holding  % of issued share capital
 Lyn Rees    CEO       73,379                               €0.3899                                73,379                        0.00%
 John Brown  Chairman  73,762                               €0.3899                                73,762                        0.00%
 Ian Gilham  NED       28,750                               £0.34415                               28,750                        0.00%

 

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Singer Capital Markets (Joint Broker)                                                                     +44 (0) 20 7496 3000
 Phil Davies / James Fischer / Samed Ethemi

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Paul McManus / Lianne Applegarth                                        +44 (0)7980 541 893 / +44 (0)7584 391 303

 Alice Woodings                                                           +44 (0)7407 804 654

 

 

 

About Novacyt Group (www.novacyt.com (http://www.novacyt.com) )

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel

 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·    Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                      whole exome sequencing (WES)

 

Novacyt is headquartered in Le Vésinet in France with offices in the UK
(Manchester), Singapore, the US and Canada and has a commercial presence in
over 65 countries, including Australia, following the recent acquisition of
Southern Cross Diagnostics in March 2026, which has opened new distribution
channels to the life sciences and diagnostics industries in the territory and
the wider Asia-Pacific region. The Company is listed on the London Stock
Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth
("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name

     1)    Lyn Rees                                               1)    CEO

     2)    John Brown                                             2)    Chairman

     3)    Ian Gilham                                             3)    NED

 2.  Reason for the Notification
 a)  Position/status                                              See 1(a) - classified as a PDMR of the Company

 b)  Initial notification/ Amendment                              Initial Notification

 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Novacyt S.A.
 b)  LEI                                                          213800BWAC2BF295EG28
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  ordinary shares of €1/15 each

     Identification code                                          FR0010397232
 b)  Nature of the transaction                                    Acquisition of Ordinary Shares

 c)  Price(s) and volume(s)

Price      Volume
     1)    Lyn Rees                                               €0.3817    15,149

                                                            €0.3919    56,438
                                                                  €0.3945    1,792

 

Price      Volume
                                                                  €0.3817    15,228

                                                            €0.3919    56,732
                                                                  €0.3950    1,802

     2)    John Brown
 

Price      Volume
                                                                  £0.34415   28,750

 

     3)    Ian Gilham
 d)  Aggregated information:

     · Aggregated volume

     · Price

Price      Volume
     1)    Lyn Rees                                               €0.3899    73,379

 

Price      Volume
                                                                  €0.3899    73,762

     2)    John Brown
 

Price      Volume
                                                                  £0.34415   28,750

 

     3)    Ian Gilham
 e)  Date of the transaction                                      1 & 2) 26 and 27 March 2026

                                                                  3) 27 March 2026

 f)  Place of the transaction                                     1 & 2) Euronext and 3) AIM

 

 Price      Volume
 €0.3817    15,228
 €0.3919    56,732
 €0.3950    1,802

 

 Price      Volume
 £0.34415   28,750

 

 

d)

Aggregated information:

· Aggregated volume

· Price

 

1)    Lyn Rees

 

 

2)    John Brown

 

 

3)    Ian Gilham

 

 

 

 

 Price      Volume
 €0.3899    73,379

 

 Price      Volume
 €0.3899    73,762

 

 Price      Volume
 £0.34415   28,750

 

 

e)

Date of the transaction

1 & 2) 26 and 27 March 2026

3) 27 March 2026

 

f)

Place of the transaction

1 & 2) Euronext and 3) AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHWPUMPWUPQGWU



            Copyright 2019 Regulatory News Service, all rights reserved